Idexx Laboratories (IDXX) Receivables (2009 - 2026)

Idexx Laboratories has reported Receivables for 18 years, with the latest figure at $709.4 million in Q2 2026.

• On a quarterly basis, Receivables rose 12.87% year-over-year to $709.4 million in Q2 2026; TTM through Jun 2026 was $709.4 million, a 12.87% increase from a year earlier, with the FY2025 full-year figure at $628.2 million, up 17.57% from the prior year.
• Receivables was $709.4 million for Q2 2026 at Idexx Laboratories, up from $681.2 million in the prior quarter.
• The five-year high for Receivables was $709.4 million in Q2 2026, with the low at $430.3 million in Q3 2022.
• Average Receivables over 5 years is $551.7 million, with a median of $549.1 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables rose 4.25% in 2024, then advanced 17.57% in 2025.
• Over 5 years, Receivables stood at $442.5 million in 2022, then climbed by 15.84% to $512.6 million in 2023, then gained by 4.25% to $534.3 million in 2024, then climbed by 17.57% to $628.2 million in 2025, then grew by 12.92% to $709.4 million in 2026.
• The last three Receivables figures came in at $709.4 million (Q2 2026), $681.2 million (Q1 2026), and $628.2 million (Q4 2025), per Business Quant data.